We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lipid Buildup in Motor Neurons May Trigger ALS

By Biotechdaily staff writers
Posted on 12 Sep 2002
Researchers have found that the buildup of large lipid molecules such as sphingomyelin, ceramides, and cholesterol esters may account for the degeneration of motor neurons that takes place in amyotrophic lateral sclerosis (ALS). More...
This finding was published August 22, 2002, in the online edition of the Annals of Neurology.

Also called Lou Gehrig's disease, ALS is a progressive, fatal neurologic disease that occurs when specific nerve cells in the brain and spinal cord that control voluntary movement gradually deteriorate. The loss of these motor neurons causes the muscles under their control to weaken and wither away, leading to paralysis.

Comparison of spinal cord tissue extracted from people who had ALS to that from normal individuals revealed that levels of ceramides, cholesterol esters, and several other lipids were significantly elevated in the spinal cords of people with ALS.

A mouse model was developed with the mutated human gene copper/zinc-superoxide dismutase (Cu/Zn-SOD) incorporated into the genome. These mice, which displayed symptoms of ALS, were found to have increased levels of ceramides and cholesterol esters in their spinal cords.

Other experiments on motor neurons in tissue culture showed that exposure to free radicals caused an increase in the levels of ceramides and cholesterol esters in the cells. On the other hand, treatment of the neurons with a drug called ISP-1, which inhibits synthesis of sphingolipids, protected the cells from the effects of oxygen free radicals. The treated cells did not accumulate ceramides or cholesterol esters and did not deteriorate.

"Based on our study, ceramide accumulation appears to be both necessary and sufficient to explain the degeneration of spinal cord motor neurons in ALS,” explained Dr. Mark Mattson, lead author of the study and chief of the Laboratory of Neurosciences at the US National Institute on Aging (Baltimore, MD, USA; www.nih.gov). "This knowledge is now being used to develop drugs that potentially could prevent these abnormalities.”



Related Links:
National Institute on Aging

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.